KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Assets (2016 - 2025)

Astrazeneca (AZN) has 3 years of Non-Current Assets data on record, last reported at $85.4 billion in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 9.13% year-over-year to $85.4 billion; the TTM value through Dec 2025 reached $85.4 billion, up 9.13%, while the annual FY2025 figure was $85.4 billion, 9.13% up from the prior year.
  • Non-Current Assets reached $85.4 billion in Q4 2025 per AZN's latest filing, up from $78.2 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $85.4 billion in Q4 2025 and bottomed at $76.1 billion in Q4 2023.
  • Average Non-Current Assets over 3 years is $79.9 billion, with a median of $78.2 billion recorded in 2024.
  • Peak YoY movement for Non-Current Assets: grew 2.82% in 2024, then rose 9.13% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $76.1 billion in 2023, then rose by 2.82% to $78.2 billion in 2024, then increased by 9.13% to $85.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $85.4 billion in Q4 2025, $78.2 billion in Q4 2024, and $76.1 billion in Q4 2023.